Read our latest updates & insights

On 2 July 2026, Singaporean-headquartered Prestige Biopharma announced that it had signed a memorandum of understanding (MOU) with US-based Charles River Laboratories to collaborate on biopharmaceutical development, testing and manufacturing.

The collaboration will c...

On 1 July 2026, The Korea Biomedical Review reported that Samsung Epis Holdings has opened and commenced operating its new research and development centre in Beijing.  The establishment of the new R&D centre was first announced by Samsung Epis on 29 May 2026.

The...

On 1 July 2026, Australia’s Pharmaceutical Benefits Scheme published its Summary of Changes, which includes a newly PBS-listed ustekinumab biosimilar and new or expanded PBS-listings for a number of biopharmaceuticals.

The newly PBS-listed ustekinumab biosimilar is A...

On 1 July 2026, Celltrion announced that the FDA has granted interchangeability status to Truxima®, biosimilar to Genentech/Biogen’s Rituxan®, making it the first rituximab biosimilar in the US to earn this designation.  As the first interchangeable rituximab biosimilar in ...

On 1 July 2026, Samsung Bioepis and Harrow announced the relaunch of Byooviz® (ranibizumab), biosimilar to Genentech’s Lucentis®, in the US.

The relaunch follows the transition of Biogen’s commercialisation rights for biosimilar ranibizumab (and biosimilar aflibercep...

On 1 July 2026, Seoul Economic Daily reported that Celltrion has launched its new Omlyclo® (omalizumab) Pen Injection 150mg, an autoinjector formulation designed for the treatment of allergic asthma and chronic idiopathic urticaria.

Celltrion announced the Korean app...

On 30 June 2026, EirGenix announced that it has signed an agreement for the licensing and commercialisation of EG1206A, biosimilar to Roche’s Perjeta® (pertuzumab), in Japan.  The partner to the deal has not been identified but is said to be a “leading Japanese pharmaceutic...